401 related articles for article (PubMed ID: 6362866)
1. Adoptive immunotherapy of cancer: accomplishments and prospects.
Rosenberg SA
Cancer Treat Rep; 1984 Jan; 68(1):233-55. PubMed ID: 6362866
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy of cancer by systemic administration of lymphoid cells plus interleukin-2.
Rosenberg SA
J Biol Response Mod; 1984 Oct; 3(5):501-11. PubMed ID: 6389777
[TBL] [Abstract][Full Text] [Related]
3. Development of long-term cell lines and lymphoid clones reactive against murine and human tumors: a new approach to the adoptive immunotherapy of cancer.
Rosenberg SA; Eberlein TJ; Grimm EA; Lotze MT; Mazumder A; Rosenstein M
Surgery; 1982 Aug; 92(2):328-36. PubMed ID: 6980492
[TBL] [Abstract][Full Text] [Related]
4. Treatment of intracranial tumors by systemic transfer of superantigen-activated tumor-draining lymph node T cells.
Inoue M; Plautz GE; Shu S
Cancer Res; 1996 Oct; 56(20):4702-8. PubMed ID: 8840987
[TBL] [Abstract][Full Text] [Related]
5. Factors related to therapeutic efficacy in adoptive chemoimmunotherapy of a Friend virus-induced lymphoma.
Fass L; Fefer A
Cancer Res; 1972 Nov; 32(11):2427-31. PubMed ID: 5082591
[No Abstract] [Full Text] [Related]
6. Importance of cyclophosphamide-induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice.
Proietti E; Greco G; Garrone B; Baccarini S; Mauri C; Venditti M; Carlei D; Belardelli F
J Clin Invest; 1998 Jan; 101(2):429-41. PubMed ID: 9435316
[TBL] [Abstract][Full Text] [Related]
7. Adoptive immunotherapy of established syngeneic solid tumors: role of T lymphoid subpopulations.
Rosenstein M; Eberlein TJ; Rosenberg SA
J Immunol; 1984 Apr; 132(4):2117-22. PubMed ID: 6607955
[TBL] [Abstract][Full Text] [Related]
8. Adoptive immunotherapy of solid tumors with activated macrophages: experimental and clinical results.
Bartholeyns J; Lopez M; Andreesen R
Anticancer Res; 1991; 11(3):1201-4. PubMed ID: 1888150
[TBL] [Abstract][Full Text] [Related]
9. The systemic administration of purified interleukin 2 enhances the ability of sensitized murine lymphocytes to cure a disseminated syngeneic lymphoma.
Donohue JH; Rosenstein M; Chang AE; Lotze MT; Robb RJ; Rosenberg SA
J Immunol; 1984 Apr; 132(4):2123-8. PubMed ID: 6607956
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy of cancer: experimental approach with activated macrophages proliferating in culture.
Bartholeyns J; Lombard Y; Dumont S; Hartmann D; Chokry M; Giaimis J; Kaufmann S; Poindron P
Cancer Detect Prev; 1988; 12(1-6):413-20. PubMed ID: 3180139
[TBL] [Abstract][Full Text] [Related]
11. Vascular attack by 5,6-dimethylxanthenone-4-acetic acid combined with B7.1 (CD80)-mediated immunotherapy overcomes immune resistance and leads to the eradication of large tumors and multiple tumor foci.
Kanwar JR; Kanwar RK; Pandey S; Ching LM; Krissansen GW
Cancer Res; 2001 Mar; 61(5):1948-56. PubMed ID: 11280751
[TBL] [Abstract][Full Text] [Related]
12. Cellular immunotherapy of cancer.
Yang JC
Curr Opin Gen Surg; 1994; ():238-44. PubMed ID: 7583979
[TBL] [Abstract][Full Text] [Related]
13. In vivo kinetics of murine lymphoid cells: in relation to local adoptive cancer immunotherapy.
Yamasaki N; Kan N; Inamoto T; Nakayama N; Nio Y; Hori T
Nihon Geka Hokan; 1984 Jan; 53(1):67-78. PubMed ID: 6333856
[No Abstract] [Full Text] [Related]
14. Type 1 CD8+ T cells are superior to type 2 CD8+ T cells in tumor immunotherapy due to their efficient cytotoxicity, prolonged survival and type 1 immune modulation.
Ye Z; Tang C; Xu S; Zhang B; Zhang X; Moyana T; Yang J; Xiang J
Cell Mol Immunol; 2007 Aug; 4(4):277-85. PubMed ID: 17764618
[TBL] [Abstract][Full Text] [Related]
15. Cancer immunogene therapy.
Yoshizawa H; Kagamu H; Gejyo F
Arch Immunol Ther Exp (Warsz); 2001; 49(5):337-43. PubMed ID: 11798131
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms of adoptive immunotherapy: improved methods for in vivo tracking of tumor-infiltrating lymphocytes and lymphokine-activated killer cells.
Wallace PK; Palmer LD; Perry-Lalley D; Bolton ES; Alexander RB; Horan PK; Yang JC; Muirhead KA
Cancer Res; 1993 May; 53(10 Suppl):2358-67. PubMed ID: 8485722
[TBL] [Abstract][Full Text] [Related]
17. B-cell depletion using an anti-CD20 antibody augments antitumor immune responses and immunotherapy in nonhematopoetic murine tumor models.
Kim S; Fridlender ZG; Dunn R; Kehry MR; Kapoor V; Blouin A; Kaiser LR; Albelda SM
J Immunother; 2008 Jun; 31(5):446-57. PubMed ID: 18463540
[TBL] [Abstract][Full Text] [Related]
18. The optimal interval for dendritic cell vaccination following adoptive T cell transfer is important for boosting potent anti-tumor immunity.
Park MY; Kim CH; Sohn HJ; Oh ST; Kim SG; Kim TG
Vaccine; 2007 Oct; 25(42):7322-30. PubMed ID: 17889413
[TBL] [Abstract][Full Text] [Related]
19. Impaired antigen presentation and effectiveness of combined active/passive immunotherapy for epithelial tumors.
Matsumoto K; Leggatt GR; Zhong J; Liu X; de Kluyver RL; Peters T; Fernando GJ; Liem A; Lambert PF; Frazer IH
J Natl Cancer Inst; 2004 Nov; 96(21):1611-9. PubMed ID: 15523090
[TBL] [Abstract][Full Text] [Related]
20. Protocol design for lymphokine testing in clinical studies of human cancer.
Lotze MT; Rosenberg SA
Lymphokine Res; 1986; 5 Suppl 1():S177-81. PubMed ID: 3784611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]